Dr. Jolene Fisher, University Health Network, Toronto, ON
Longitudinal monitoring of patients with fibrotic interstitial lung disease (ILD) is essential to identifying disease progression and guiding management decisions. Routine assessment of pulmonary symptoms and physiology are important for physician decision-making surrounding initiation or altering of ILD medications and the timing of lung transplant and/or palliative care referrals. Patients with fibrotic ILD are at increased risk for certain respiratory and non-respiratory comorbidities and these are important considerations in long-term monitoring. This presentation will summarize the key components of long-term monitoring of fibrotic ILD, including the appropriate frequency of monitoring, specific symptoms to consider and the objective testing that should be routinely performed. Identifying disease progression and how it influences management decisions will be addressed.
At the end of this presentation, attendees will be able to:
- determine the appropriate timing and frequency of longitudinal monitoring of fibrotic ILD, including specific symptoms and testing to consider at each patient encounter;
- define disease progression in fibrotic ILD; and
- summarize how disease progression influences management decisions for patients with fibrotic ILD.